LENZ THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
LENZ THERAPEUTICS, INC. (LENZ) reported Increase (Decrease) in Accounts Payable of $2.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$4.28M.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $6.76M.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$156.00K, a 111.82% decline year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.69M.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$90.00K.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$4.28M, a 599.88% decline from fiscal 2023.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $856.00K, a 341.24% increase from fiscal 2022.
- LENZ THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $194.00K, a 89.37% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.48M 10-Q · filed 2026-08-11 | $2.33M derived: sum of 3 quarters · filed 2026-08-11 | $4.02M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $6.76M 10-Q · filed 2026-05-11 | $6.61M derived: sum of 2 quarters · filed 2026-05-11 | $8.30M derived: sum of 3 quarters · filed 2026-05-11 | $7.44M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.54M derived: sum of 2 quarters · filed 2026-03-24 | $681.00K derived: sum of 3 quarters · filed 2026-08-11 | -$90.00K 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $837.00K derived: sum of 2 quarters · filed 2026-08-11 | $66.00K 10-Q · filed 2025-11-05 | $1.39M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$857.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.63M 10-Q · filed 2026-08-11 | -$308.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.95M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$771.00K 10-Q · filed 2026-05-11 | $549.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.09M derived: sum of 3 quarters · filed 2026-05-11 | -$3.78M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$324.00K derived: sum of 2 quarters · filed 2026-03-24 | -$3.01M derived: sum of 3 quarters · filed 2026-03-24 | -$4.28M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.33M derived: sum of 2 quarters · filed 2025-11-05 | -$5.60M 10-Q · filed 2025-11-05 | -$4.51M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$3.96M 10-Q · filed 2025-07-30 | -$2.87M derived: sum of 3 quarters · filed 2025-07-30 | -$898.00K derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2024-03-31 | -$1.27M 10-Q · filed 2025-05-07 | -$181.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.79M derived: sum of 3 quarters · filed 2025-05-07 | $154.00K derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $3.06M derived: sum of 2 quarters · filed 2025-03-19 | $1.42M derived: sum of 3 quarters · filed 2025-03-19 | $856.00K 10-K · filed 2025-03-19 | -$2.36M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $335.00K derived: sum of 2 quarters · filed 2024-11-06 | -$232.00K 10-Q · filed 2024-11-06 | $1.15M 10-Q · filed 2023-11-13 | -$1.31M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.20M 10-Q · filed 2024-08-14 | -$1.09M 10-Q · filed 2023-08-14 | -$3.28M derived: sum of 3 quarters · filed 2024-08-14 | -$2.89M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | -$567.00K 10-Q · filed 2024-05-08 | -$591.00K 10-Q · filed 2023-05-11 | -$1.65M derived: sum of 2 quarters · filed 2024-05-08 | -$1.26M derived: sum of 3 quarters · filed 2024-05-08 | -$955.00K derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$689.00K derived: sum of 2 quarters · filed 2024-02-27 | -$388.00K derived: sum of 3 quarters · filed 2024-02-27 | $194.00K 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $392.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $693.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.27M 10-Q · filed 2023-11-13 | $1.99M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $301.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $883.00K 10-Q · filed 2023-08-14 | $1.59M derived: sum of 3 quarters · filed 2023-08-14 | -$743.00K derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $582.00K 10-Q · filed 2023-05-11 | $1.29M derived: sum of 2 quarters · filed 2023-05-11 | -$1.04M derived: sum of 3 quarters · filed 2023-05-11 | $2.32M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $710.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$1.63M derived: sum of 2 quarters · filed 2023-03-20 | $1.74M derived: sum of 3 quarters · filed 2023-03-20 | $1.82M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.03M derived: sum of 2 quarters · filed 2022-11-09 | $1.11M 10-Q · filed 2022-11-09 | $1.32M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.45M 10-Q · filed 2022-08-11 | $3.65M derived: sum of 3 quarters · filed 2022-08-11 | $3.77M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $83.00K 10-Q · filed 2022-05-12 | $284.00K derived: sum of 2 quarters · filed 2022-05-12 | $397.00K derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $314.00K derived: sum of 2 quarters · filed 2022-03-21 | $594.00K 10-K · filed 2022-03-21 | |||||
| 2020-09-30 | $113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $393.00K 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $280.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |